Trials / Completed
CompletedNCT03696108
A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)
A Phase 3, Randomized, Double-blind Clinical Study to Evaluate the Long-term Safety and Efficacy of MK-7264 in Japanese Adult Participants With Refractory or Unexplained Chronic Cough
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 175 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety of two doses of gefapixant (MK-7264) in Japanese adult participants with refractory or unexplained chronic cough.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefapixant | Gefapixant 15 mg or 45 mg tablet administered orally BID |
| DRUG | Placebo | Placebo matched to gefapixant 15 mg or 45 mg administered orally BID |
Timeline
- Start date
- 2018-10-31
- Primary completion
- 2020-10-07
- Completion
- 2020-10-07
- First posted
- 2018-10-04
- Last updated
- 2021-11-01
- Results posted
- 2021-11-01
Locations
61 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03696108. Inclusion in this directory is not an endorsement.